Panobinostat combination demonstrates benefit in relapsed/refractory multiple myeloma
the ONA take:
According to results presented at the 20th Congress of the European Hematology Association, researchers have found that patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone if they have received at least two prior treatment regimens, including an immunomodulatory agent and bortezomib.
The subgroup analysis, which included 147 patients, demonstrated a 12.5-month progression-free survival for patients who had received at least 2 prior regimens and received panobinostat compared with a progression-free survival of 4.7 months with placebo.
The overall study showed a 3.9-month improvement in median progression-free survival with panobinostat versus placebo.
"Together, these data identify the subgroup of patients with relapsed or relapsed and refractory [multiple myeloma] who benefits most with panobinostat-bortezomib-dexamethasone," Dr. Hermann Einsele, director of the Medical Clinic at University of Wurzberg in Germany said. "The findings support the recent [Food and Drug Administration] approval of the panobinostat combination in [multiple myeloma] patients who received ≥2 prior regimens, including IMiDs and bortezomib."
Patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|